ArticleFrontiers in pharmacology2026
The lipid-modulating effect of berberine in hyperlipidemic ApoE-/- mice.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Berberine, a natural alkaloid from plants of the genus Coptis, shows significant lipid-lowering effects clinically. However, its exact mechanism in lipid metabolism is not fully understood. Sigma-1 receptor probes offer advantages such as strong Objective: This study investigates the mechanism by which berberine improves lipid metabolism in ApoE-/- mice using Sigma-1 receptor probes. Methods: ApoE-/- hyperlipidemic mice were used as the model. Berberine treatment effects on lipid profiles were measured. Hepatic lipid metabolism was evaluated with Oil Red O staining. Sigma-1 receptor expression in mouse tissues was analyzed using [ Results: After 6 weeks of treatment, berberine significantly reduced serum total cholesterol and low-density lipoprotein cholesterol levels, ameliorated hepatic lipid deposition, and upregulated the expression of hepatic Sigma-1 receptor in hyperlipidemic ApoE-/- mice. Conclusion: Berberine effectively improved dyslipidemia and hepatic lipid deposition in hyperlipidemic mice, which may be related to the modulation of hepatic Sigma-1 receptor expression, though the precise mechanism requires further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.